{"id":"W2900483456","doi":"10.1093/annonc/mdy425.002","title":"Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Carboplatin; Pembrolizumab; Paclitaxel; Internal medicine; Clinical endpoint; Placebo; Oncology; Randomization; Taxane; Progression-free survival; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin; Pathology; Immunotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002192634,0.000915671,0.002342882,0.0004492009,0.00030681,0.001063845,0.0006658458,0.0007672913,0.00278347],"category_scores_gemma":[0.0009724698,0.0003564087,0.003850087,0.0007703592,0.0004048053,0.001329832,0.0006222717,0.002233628,0.0007179207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001232681,"about_ca_system_score_gemma":0.001636619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002545084,"about_ca_topic_score_gemma":0.007297242,"domain_scores_codex":[0.9992496,0.0002442123,0.0000751144,0.0001375519,0.0000826219,0.0002107327],"domain_scores_gemma":[0.9992811,0.0001488331,0.000142911,0.0001048957,0.00006355008,0.0002587003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7862112,0.01086412,0.02878363,0.00172653,0.009843585,0.0001588787,0.0002370403,0.001485704,0.006543201,0.0002153693,0.005027378,0.1489033],"study_design_scores_gemma":[0.3986724,0.3070656,0.2359999,0.0006402368,0.03085359,0.0007788059,0.0007335606,0.001389044,0.006089974,0.0007435856,0.01688855,0.0001447125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763123,0.01367647,0.0002542509,0.000638062,0.0002739151,0.0005582828,0.003208214,0.00005358051,0.005024809],"genre_scores_gemma":[0.9739965,0.01241136,0.0008094184,0.002254288,0.0005164872,0.0006189535,0.005633009,0.00007400937,0.003686058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00278347,"threshold_uncertainty_score":0.0115959,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09552856974600375,"score_gpt":0.3729229509370275,"score_spread":0.2773943811910238,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}